What exactly are 'nonsense mutations' and premature stop codons, and how could tRNA hold the key to treating thousands of #rarediseases caused by these genetic changes? Alltrna’s CEO Michelle Werner talks to Larry Luxner of Rare Disease Advisor about how these mutations are found across all genetic diseases, the promise of tRNA medicines, and her personal connection to Duchenne muscular dystrophy. Read the article and listen to the interview here: https://lnkd.in/gsDAnnd8 #tRNA #RNA #tRNAmedicines #tRNAbiology #rarediseases #raredisease #StopCodonDisease #geneticmedicines #programmablemedicines #Duchenne #musculardystrophy
Alltrna
生物技术研究
Cambridge，Massachusetts 6,966 位关注者
The world’s first transfer RNA (tRNA) platform company. We are unlocking the vast therapeutic potential within #tRNA.
关于我们
Alltrna is the first transfer RNA (tRNA) platform company, and our mission is to unlock tRNA biology and pioneer tRNA therapeutics to regulate the protein universe and resolve disease. Founded at Flagship Labs in 2018, Alltrna has mapped tRNA biology to systematically design tRNA medicines and encode a completely new, unifying approach to treating both rare and common human diseases driven by shared genetic mutations. Alltrna’s platform combines internal expertise and proprietary machine learning tools to unlock the entire tRNA biology space. We have an unprecedented opportunity to advance a single tRNA medicine to restore disrupted protein production, regardless of target, for thousands of diseases with the same underlying genetic mutation.
- 网站
-
https://www.alltrna.com
Alltrna的外部链接
- 所属行业
- 生物技术研究
- 规模
- 11-50 人
- 总部
- Cambridge，Massachusetts
- 类型
- 私人持股
- 创立
- 2018
地点
-
主要
获取路线
US，Massachusetts，Cambridge
Alltrna员工
动态
-
Our CEO Michelle Werner will be speaking at the annual #STATSummit in #Boston on October 17, 2024, about her personal and professional quest to transform and accelerate rare disease drug development. See the agenda from STAT here: https://lnkd.in/dgCtmqXM?
-
-
We are beyond proud to share that our CEO, Michelle Werner, has been named to Endpoints News’ annual ?????????? ???? ?????????????????? list! ?? Her leadership inspires us everyday at Alltrna to push the boundaries of innovation in tRNA therapeutics and give it our all to do more for patients. Congratulations, Michelle, on this well-deserved recognition! See more at Endpoints News: https://lnkd.in/g9Wp3bxv #WomenInBiopharma #tRNAmedicines #tRNA #rarediseases #raredisease #StopCodonDisease #geneticmedicines #programmablemedicines #AI #machinelearning
-
-
Alltrna’s CEO Michelle Werner will be speaking at the Axiom Crossroads Summit on October 10, 2024 at MassBio in a fireside chat with Hafiz Sikder of Axiom Healthcare Strategies. Michelle will be discussing strategies, including basket clinical trials, that have the potential to accelerate #raredisease #drugdevelopment. See more here: https://lnkd.in/gMiXTg2d #tRNA #tRNAmedicines
-
-
Could a mutation-specific, disease-agnostic approach transform drug development for thousands of patients without disease-modifying therapies? And what needs to be done to bring basket clinical trials that have been increasingly used to accelerate drug development in oncology into the rare disease space? Alltrna CEO Michelle Werner and SVP of Discovery Platform Caroline K?hrer recently sat down with Ellen Capon of Drug Target Review to talk about tRNA and how it can be leveraged to scale the development of genetic medicines. ?? To learn more, listen to the this short 15-minute podcast: https://lnkd.in/gCHp-Jc2 #InternationalPodcastDay #tRNA #RNA #tRNAmedicines #tRNAbiology #rarediseases #geneticmedicines #programmablemedicines #StopCodonDisease
-
Being a pioneer in your field is exciting, but it also comes with some unique challenges. When Alltrna started, there was no pre-existing framework for the production of chemically modified tRNAs. Over the years, the team has pioneered many of the processes and technologies to advance our first engineered tRNA medicines towards the clinic. In this insightful interview with David McCall of BioInsights, our Chief Technology Officer William Kiesman talks about what it is like leading such an innovative team and the processes it has developed, including product synthesis and scaling, proprietary analytical techniques to understand impurity profiles and inform downstream purification steps, and other drug design and quality control steps. He also discusses further advancements the field will need, including: ??the use of more ecologically sustainable, enzymatic processes to reduce waste ??the ligation of smaller oligonucleotides to make bigger, more complex systems ??innovations in oligonucleotide delivery to cells ??Register for free to read the article in Nucleic Acid Insights: https://lnkd.in/grXYeGcn #tRNA #RNA #tRNAmedicines #tRNAbiology #rarediseases #StopCodonDisease #geneticmedicines #programmablemedicines?
-
Our CEO Michelle Werner will present at Chardan’s 8th Annual Genetic Medicines Conference, where she'll discuss our latest research in advancing novel tRNA medicines to scale and accelerate the development of new genetic medicines, in a way no other therapeutic modality can. Michelle will be presenting on Monday, September 30th at 1pm ET. Request info about the conference from Chardan here: https://lnkd.in/gchdEUBH #ChardanGMConf #tRNA #RNA #AI #machinelearning #geneticmedicines #StopCodonDisease
-
-
When Arnold Groehler IV was studying medicinal chemistry in Wisconsin and Minnesota, RNA was not a drug target that was often discussed, and tRNA was barely on his radar. So being able to work on tRNA now, a novel modality in a novel scientific space, is one of the things that most excites him about his job as a scientist at Alltrna. And learning something new about the ever-changing field of mass spectrometry is an added bonus. ?? Learn more about what makes Arnie tick in our latest Employee Spotlight video. #WeAreAlltrna #lablife #tRNAbiology #LCMS #MassSpec #tRNAmedicines
-
We are so excited to share that FierceHealth and Fierce Life Sciences have named Alltrna’s CEO Michelle Werner as one of ????????’?? #???????????????? ????????????????! It’s great to see the recognition for her leadership at Alltrna as we pioneer #tRNA medicines and her commitment to innovation, equity, and improving patient lives – especially those with rare diseases. Read the profile here: https://lnkd.in/gBEHQeVe Congrats Michelle and thank you for all you do! #PatientAdvocacy #tRNAmedicines #rarediseases #raredisease #StopCodonDisease #geneticmedicines #programmablemedicines
-
-
While families with Duchenne muscular dystrophy have more hope than ever before, they are also feeling overwhelmed, anxious, and confused. To mark World Duchenne Awareness Day, Alltrna CEO Michelle Werner raises her voice for Duchenne and shares the agonizing decision she faced on behalf of her teenage son, and what needs to be done to support families like her own. #Duchenne #musculardystrophy #WorldDuchenneAwarenessDay #DuchenneActionMonth #WDAD2024 #MuscularDystrophyAwarenessMonth #30DaysOfStrength
Duchenne muscular dystrophy has seen more progress in the past 15 months (give or take) than in the last couple of decades combined, with three new therapies approved by the FDA, including the gene therapy Elevidys. But what I think many in the field fail to understand is that while families now have more hope, they are also feeling overwhelmed, anxious, confused, and, quite frankly, scared to death. As many of you know, I'm not only the CEO of Alltrna, but I'm also the mother of a child with Duchenne. My husband and I agonized over the decision about whether to seek treatment with Elevidys for our son Caffrey, which comes with considerations that could last a lifetime. Ultimately it was Caffrey, now 14, who made the final decision, opting not to pursue the treatment. As I outline in this STAT?First Opinion article and as we recognize during this year’s World Duchenne Awareness Day, parents need to step up as advocates for their kids like never before. And when the stakes are so high and the decision is so personal, the most critical thing families need is judgment-free support. It has been a historic year, one that makes me so optimistic about the future, but let’s remember that Duchenne is far from being solved. We cannot stop innovating until this is achieved. Read the First Opinion article:?https://lnkd.in/e7qmKQuK #Duchenne #musculardystrophy #WorldDuchenneAwarenessDay #DuchenneActionMonth #WDAD2024 #MuscularDystrophyAwarenessMonth #30DaysOfStrength